Scarica l'app Stockscreener
17.15
5.80%
0.94
Dopo l'orario di chiusura:
17.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Chart overlay techniques for tracking Arcutis Biotherapeutics Inc.Weekly Trend Report & Consistent Income Trade Ideas - Newser
Using Ichimoku Cloud for Arcutis Biotherapeutics Inc. technicals2025 Market Trends & Verified Entry Point Signals - Newser
ranking arcutis biotherapeutics inc. among high performing stocks via toolsWatch List & Daily Market Momentum Tracking - Newser
Arcutis Biotherapeutics’ Use of Inducement Grants: Strategic Talent Retention or Market Signal? - AInvest
Is Arcutis Biotherapeutics Inc. a defensive stockJuly 2025 News Drivers & Daily Profit Focused Screening - خودرو بانک
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
What’s the outlook for Arcutis Biotherapeutics Inc.’s sector2025 Retail Activity & Risk Managed Investment Entry Signals - خودرو بانک
35,500 Restricted Stock Units: Arcutis Biotherapeutics Grants Equity Awards to New Immuno-Dermatology Team - Stock Titan
Relative strength of Arcutis Biotherapeutics Inc. in sector analysisDividend Hike & Growth Oriented Trading Recommendations - Newser
Long term hold vs stop loss in Arcutis Biotherapeutics Inc.Quarterly Profit Review & Consistent Profit Trading Strategies - Newser
Ranking Arcutis Biotherapeutics Inc. among high performing stocks via toolsWeekly Volume Report & Weekly Breakout Opportunity Watchlist - Newser
What are the risks of holding Arcutis Biotherapeutics Inc.2025 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - 강소기업뉴스
Is Arcutis Biotherapeutics Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Report & Stepwise Trade Signal Implementation - Newser
Arcutis Biotherapeutics Inc. stock retracement – recovery analysis2025 Analyst Calls & Entry Point Strategy Guides - Newser
August's FDA Focus: Approvals and pipeline updates in pediatrics - Contemporary Pediatrics
Why is Arcutis Biotherapeutics Inc. stock going upWeekly Profit Recap & Proven Capital Preservation Methods - خودرو بانک
What’s the beta of Arcutis Biotherapeutics Inc. stockJuly 2025 WrapUp & Capital Efficiency Focused Strategies - خودرو بانک
Arcutis seeks FDA approval for psoriasis cream for young children By Investing.com - Investing.com Australia
Live market analysis of Arcutis Biotherapeutics Inc.July 2025 Action & Technical Pattern Based Buy Signals - Newser
Will Arcutis Biotherapeutics Inc. continue its uptrend2025 Earnings Impact & Technical Analysis for Trade Confirmation - Newser
What are analysts’ price targets for Arcutis Biotherapeutics Inc.2025 Investor Takeaways & Daily Profit Maximizing Tips - خودرو بانک
Detecting support and resistance levels for Arcutis Biotherapeutics Inc.July 2025 Gainers & Low Drawdown Investment Strategies - Newser
Will Arcutis Biotherapeutics Inc. rebound enough to break evenPortfolio Value Summary & Verified Swing Trading Watchlist - Newser
What technical models suggest about Arcutis Biotherapeutics Inc.’s comeback2025 EndofYear Setup & Safe Swing Trade Setups - Newser
Chart based analysis of Arcutis Biotherapeutics Inc. trends2025 Earnings Impact & Capital Protection Trading Alerts - Newser
Will Arcutis Biotherapeutics Inc. bounce back from current supportMarket Volume Report & Free High Accuracy Swing Entry Alerts - Newser
When Can We Expect A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)? - 富途牛牛
Arcutis submits sNDA for roflumilast cream 0.3% for treatment of psoriasis in children 2-5 years - Contemporary Pediatrics
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight - GlobeNewswire Inc.
Arcutis Seeks Expanded Indication for Zoryve - MarketScreener
Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 Years - HCPLive
Arcutis seeks FDA approval for psoriasis cream for young children - Investing.com
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 - The Manila Times
Arcutis Biotherapeutics Submits Application for ZORYVE Cream as First Topical Treatment for Plaque Psoriasis in Children Ages 2 and Up - Quiver Quantitative
First-Ever PDE4 Inhibitor for Toddlers: Arcutis' ZORYVE Aims to Transform Psoriasis Treatment Ages 2-5 - Stock Titan
Developing predictive dashboards with Arcutis Biotherapeutics Inc. dataOil Prices & Weekly Watchlist of Top Performers - Newser
Former Arcutis CTO with 52 US Patents Joins Palvella Therapeutics to Expand Rare Skin Disease Platform - Stock Titan
Using Bollinger Bands to evaluate Arcutis Biotherapeutics Inc.July 2025 Big Picture & Step-by-Step Swing Trade Plans - Newser
What high frequency data says about Arcutis Biotherapeutics Inc.Trade Risk Summary & Stepwise Entry and Exit Trade Signals - Newser
What is Arcutis Biotherapeutics Inc. s 5 year growth outlookQuarterly Risk Review & Free Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Arcutis Biotherapeutics Inc. stock a smart retirement pick2025 Investor Takeaways & Real-Time Volume Spike Alerts - خودرو بانک
HCPLive 5 Stories in Under 5: Week of 08/24 - HCP Live
Can Arcutis Biotherapeutics Inc. sustain earnings growthMarket Weekly Review & Precise Entry and Exit Recommendations - خودرو بانک
Will Arcutis Biotherapeutics Inc. benefit from current market trendsEarnings Summary Report & Growth Oriented Trading Recommendations - خودرو بانک
Is Arcutis Biotherapeutics Inc. backed by strong institutional buyingJuly 2025 Retail & Reliable Entry Point Trade Alerts - خودرو بانک
Can Arcutis Biotherapeutics Inc. stock double in the next yearInsider Buying & Technical Analysis for Trade Confirmation - خودرو بانک
Is Arcutis Biotherapeutics Inc. stock showing strong momentum2025 Performance Recap & Low Drawdown Momentum Trade Ideas - خودرو بانک
Is Arcutis Biotherapeutics Inc. forming a bullish divergence2025 Buyback Activity & Proven Capital Preservation Methods - خودرو بانک
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? - sharewise.com
1.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):